The lack of a sensitive and specific biomarker for early detection of prostate cancer (PCa) is a major obstacle to the effective treatment of these patients. This study aimed to study the volatile urinary metabolic profile of PCa patients (n=58) and control individuals (cancer-free, n=60), to identify a potential panel of biomarkers for non-invasive PCa detection. The results obtained revealed a panel of biomarkers with 6 volatile compounds, which was able to identify this type of cancer with a sensitivity, specificity and accuracy of 89%, 83% and 86%, respectively.